The development of targeted anticancer therapies has emerged as a promising approach to improve the efficacy and specificity of cancer treatment. This study focuses on the innovative design and synthesis of novel anticancer compounds that selectively target specific signaling pathways involved in cancer progression. By utilizing advanced computational modeling and medicinal chemistry techniques, we have identified and synthesized a series of compounds with high affinity for critical molecular targets. In vitro and in vivo evaluations demonstrate that these novel agents effectively inhibit cancer cell proliferation and induce apoptosis with minimal impact on normal cells. The findings underscore the potential of pathway-specific targeting as a strategy for developing safer and more effective anticancer therapies.